Omeros Corporation (OMER)
OMER Stock Price Chart
Explore Omeros Corporation interactive price chart. Choose custom timeframes to analyze OMER price movements and trends.
OMER Company Profile
Discover essential business fundamentals and corporate details for Omeros Corporation (OMER) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Oct 2009
Employees
202.00
Website
https://www.omeros.comCEO
Gregory A. Demopulos
Description
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
OMER Financial Timeline
Browse a chronological timeline of Omeros Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.27, while revenue estimate is $12.66m.
Earnings released on 13 May 2026
EPS came in at -$0.24 surpassing the estimated -$0.40 by +40.00%, while revenue for the quarter reached $9.90m , beating expectations by +136.42%.
Earnings released on 31 Mar 2026
EPS came in at $3.14 surpassing the estimated -$0.55 by +670.91%.
Earnings released on 13 Nov 2025
EPS came in at -$0.19 surpassing the estimated -$0.58 by +67.24%.
Earnings released on 14 Aug 2025
EPS came in at -$0.53 surpassing the estimated -$0.55 by +3.64%.
Earnings released on 15 May 2025
EPS came in at -$0.65 falling short of the estimated -$0.57 by -14.04%.
Earnings released on 31 Mar 2025
EPS came in at -$0.63 surpassing the estimated -$0.78 by +19.23%, while revenue for the quarter reached $412.00k .
Earnings released on 13 Nov 2024
EPS came in at -$0.64 surpassing the estimated -$0.70 by +8.57%.
Earnings released on 7 Aug 2024
EPS came in at -$1.12 surpassing the estimated -$1.14 by +1.75%.
Earnings released on 15 May 2024
EPS came in at -$0.74 falling short of the estimated -$0.58 by -27.59%.
Earnings released on 1 Apr 2024
EPS came in at -$0.63 falling short of the estimated -$0.56 by -12.50%, while revenue for the quarter reached $1.37m .
Earnings released on 9 Nov 2023
EPS came in at -$0.82 falling short of the estimated -$0.62 by -32.26%.
Earnings released on 9 Aug 2023
EPS came in at -$0.70 falling short of the estimated -$0.60 by -16.67%.
Earnings released on 9 May 2023
EPS came in at -$0.63 falling short of the estimated -$0.55 by -14.55%.
Earnings released on 13 Mar 2023
EPS came in at -$0.73 falling short of the estimated -$0.57 by -28.07%.
Earnings released on 9 Nov 2022
EPS came in at -$0.87 falling short of the estimated -$0.61 by -42.62%.
Earnings released on 9 Aug 2022
EPS came in at -$0.60 surpassing the estimated -$0.68 by +11.76%, while revenue for the quarter reached $10.10m .
Earnings released on 10 May 2022
EPS came in at -$0.56 surpassing the estimated -$0.74 by +24.32%, while revenue for the quarter reached $27.70m , beating expectations by +171.24%.
Earnings released on 1 Mar 2022
EPS came in at -$0.37 falling short of the estimated -$0.30 by -23.33%, while revenue for the quarter reached $79.89m , beating expectations by +19.38%.
Earnings released on 9 Nov 2021
EPS came in at -$0.26 surpassing the estimated -$0.45 by +42.22%, while revenue for the quarter reached $30.00m , missing expectations by -0.48%.
Earnings released on 9 Aug 2021
EPS came in at -$0.40 surpassing the estimated -$0.50 by +20.00%, while revenue for the quarter reached $28.82m , beating expectations by +25.37%.
OMER Stock Performance
Access detailed OMER performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
